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Abstract
This anesthetic drug may cause a rare condition named propofol infusion syndrome, charac-
terized by unexplained lactic acidosis, lipemia, rhabdomyolysis, cardiovascular collapse and
Brugada-like electrocardiographic pattern or Brugada electrocardiographic phenocopy changes
following high-dose propofol infusion over prolonged periods of time.
Several articles have contributed to our understanding of the cause of the syndrome, and the
growing number of case reports has made it possible to identify several risk factors. Uncer-
tainty remains as to whether a genetic susceptibility exists.
The favorable recovery profile associated with propofol offers advantages over traditional
anesthetics in clinical situations in which rapid recovery is important. Propofol is a safe
anesthetic agent, but propofol infusion syndrome is a rare lethal complication. (Cardiol J 2010;
17, 2: 130–135)
Key words: propofol mechanisms, indications, phenocopies, adverse effects,
Brugada electrocardiographic-like pattern,
Introduction
Propofol (2,6-diisopropylphenol, INN, brand
name: Diprivan by AstraZeneca) is a short-acting,
intravenously administered sedative-hypnotic, and
antiepileptic agent with anesthetic properties un-
related to barbiturates. It is also a reliable, safe and
prompt anesthetic agent when used during induced
cardiovascular and pulmonary-impaired conditions
without surgery, or to induce anesthesia prior to
inhalant anesthesia with and without surgery. The
favorable recovery profile associated with propofol
offers advantages over traditional anesthetics in
clinical situations in which rapid recovery is impor-
tant. This drug has largely replaced sodium thiopen-
tal (Pentothal) for induction of anesthesia, as recov-
ery from propofol is more rapid and 'clear' as com-
pared to thiopental. Additionally, the drug has
antioxidant properties (propofol-nitrous oxide) se-
condary to its phenol-based chemical structure. In
elderly patients, compared to isoflurane, propofol
intravenous anesthesia is associated with rapid
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recovery of the cognitive function, stable surgical
stress response, and reduced adverse effects [1].
Propofol is also being increasingly used for sedation.
Treatment with propofol has been found to at-
tenuate oxidative stress and prevent ischemia/rep-
erfusion injury in rat hearts. Propofol protects car-
diac H9c2 cells from hydrogen peroxide (H(2)O(2))-
-induced injury by triggering the activation of Akt
and a parallel up-regulation of Bcl-2. Pretreatment
with propofol significantly protects against
H(2)O(2)-induced injury. Propofol activates the
PI3K-Akt signaling pathway. The protective effect
of propofol on H(2)O(2)-induced injury is reversed
by the PI3K inhibitor wortmannin, which effectively
suppresses propofol-induced activation of Akt, up-
regulation of Bcl-2, and protection from apoptosis.
There is a new mechanism by which propofol in-
hibits H(2)O(2)-induced injury in cardiac H9c2 cells,
supporting a potential application of propofol as
a pre-emptive cardioprotectant in clinical settings
such as that during coronary bypass surgery [2].
Mitochondrial NADH oxidase is a key enzyme in-
volved in ischemia-reperfusion-induced oxidant
generation, and it is suggested it can be a possible
target in cardioprotective strategies against is-
chemia-reperfusion injury, a condition of great im-
portance in human pathology [3]. Studies have
pointed out the involvement of the basal forebrain
gamma-aminobutyric acid-mediated system in me-
diating the effects of general anesthesia. In a study,
Laalou et al. [4] asked whether the basal forebrain
cholinergic system is also involved in mediating the
effects of general anesthetics such as propofol. The
anesthetic potency of propofol was increased in all
rats with hippocampal lesions, whatever the injec-
tion sites, compared with controls. These results
demonstrate that a cholinergic dysfunction in the
basal forebrain potentiates the anesthetic effects of
propofol.
Ketamine, propofol, and etomidate, with anes-
thetic doses, denoted efficacious effects on is-
chemia-reperfusion injury (IRI); hence the drugs
might be preferred in certain operations with the
risk of IRI [5].
Propofol is used to induce anesthesia during
a cardiac ablation procedure.
The drug's uses include general anesthesia,
sedation for mechanically ventilated adults, proce-
dural sedation and in patients with refractory sta-
tus epilepticus [6]. Bandschapp et al. [7] investigat-
ed the in vitro effects of various anesthetic agents
on pharmacologically induced chloride channel myo-
tonia. In vitro data implies that propofol adminis-
tration for general anesthesia may be better suited
to patients with chloride channel myotonia rather
than volatile anesthetics. In isolated swine skele-
tal muscle bundles, propofol elicited a reversal of
9-anthracenecarboxylic acid-induced chloride chan-
nel myotonia, whereas volatile anesthetics further
increased the associated myotonic reactions.
Propofol is also commonly used in veterinary
medicine and can be safely and effectively used for
the induction and maintenance of anesthesia in nor-
mal healthy dogs and cats [8].
Propofol is approved for use in more than
50 countries, and generic versions are available.
Table 1 shows the main adverse effects.
1. Low blood pressure (mainly through
vasodilatation). In hypovolemic patients and
those with limited cardiac reserve, even small
induction doses of propofol (0.75–1.5 mg/kg IV)
can produce profound hypotension [9]. Propo-
fol induces endothelial nitric oxide synthase
phosphorylation and activation in human umbi-
lical vein endothelial cells by inhibiting prote-
in kinase C delta expression. Propofol induces
eNOS activation through a PKC delta inhibi-
tion-dependent, protein phosphatase 2A-co-or-
dinated, but phosphoinositide 3-kinase/Akt-in-
dependent, pathway.
2. Pain on injection. Especially in smaller ve-
ins, pain is very frequent. This pain can be mi-
tigated by pre-treatment. Paracetamol 1 mg/kg
and lidocaine 0.5 mg/kg were equally effective
in attenuating pain during intravenous (IV) in-
jection of propofol; whereas pre-treatment with
paracetamol 2 mg/kg was shown to be the most
effective treatment [10].
3. Transient apnea following induction doses.
Dexmedetomidine provided an acceptable le-
Table 1. Main adverse effects of propofol.
Hypotension
Local pain on injection
Transient apnea
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vel of anesthesia for magnetic resonance ima-
ging (MRI) sleep studies in children with ob-
structive sleep apnea (OSA), producing a high
yield of interpretable studies of the patient's
native airway. The need for artificial airway
support during the MRI sleep study was signi-
ficantly less with dexmedetomidine than with
propofol. Dexmedetomidine may be the prefer-
red drug for anesthesia during MRI sleep studies
in children with a history of severe OSA, and may
offer benefits to children with sleep-disordered
breathing requiring anesthesia or anesthesia for
other diagnostic imaging studies [11].
4. Profound sedation with small doses. Repro-
ducible automated responsiveness monitor
(ARM) dynamics in individual subjects compa-
res favorably with clinical and electroencepha-
logram sedation end points, and suggests that
the ARM could be used as an independent in-
strumental guide of drug effect during propo-
fol-only sedation [12].
5. Mild myoclonic movements are common, as
with other intravenous hypnotic agents [13].
6. Seizures during intravenous propofol
anesthesia [14].
7. Euphoria (mild), hallucinations, and sexual
disinhibition. Hedonic and rewarding states
like these are modulated by the dopaminergic
system in the nucleus accumbens, prefrontal
cortex and also in the ventral pallidum and by
the glutamatergic system in the neocortex and
limbic system. Application of propofol decreased
dopamine levels in the ventral pallidum. This
effect seems to be mainly mediated through
GABAA receptors, since it was compensated by
the GABAA receptor antagonist bicuculline.
Propofol and propofol plus bicuculline exerted
no effect on glutamate release in this brain re-
gion. The reduced dopamine release in ventral
pallidum was most probably mediated through
a GABAergic feedback loop from the ventral
pallidum via the nucleus accumbens to the do-
paminergic neurons of the ventral tegmental
area or by long loop feedback. As an increase
rather than a decrease of dopamine release in
the ventral pallidum is involved in hedonic and
rewarding properties, similar symptoms indu-
ced by propofol seem to be unrelated to an ac-
tion of propofol in the ventral pallidum [15].
8. Mitochondrial disorders encompass a gro-
up of syndromes produced by genetic defects
that disrupt mitochondrial energy production.
The impaired mitochondrial energy supply af-
fects nearly all organs and tissues leading to
a variable clinical presentation. The possible
multisystem involvement complicates the ma-
nagement of anesthesia and perioperative care.
Exact knowledge of the path physiology of mi-
tochondrial diseases may help to avoid perio-
perative anesthesiological complications.
Drugs which more frequently than in the ge-
neral population cause side effects in patients
with mitochondrial disorders include steroids,
propofol, statins, fibrates, neuroleptics, and
anti-retroviral agents [16].
9. Priapism induction in some individuals [17].
10. Addiction. Such use of the drug has been de-
scribed among medical staff such as anestheti-
sts who have access to it [18, 19].
11. Dystonia or status dystonicus. It is a rare and
severe threatening disorder that develops in
patients with both primary and secondary dys-
tonia, characterized by acute worsening of
symptoms with generalized and severe musc-
le contractions [20]. Chronic posthypoxic myo-
clonus, also known as Lance-Adams syndro-
me, is a rare and devastating complication of
near-fatal cardiopulmonary arrest (successful
cardiopulmonary resuscitation), often accom-
panied by action myoclonus and cerebellar ata-
xia. It is characterized by intention myoclonus
but preserved intellect. Despite treatment with
available anti-myoclonic agents, some patients
may recover cognitively but remain complete-
ly disabled by severe myoclonus. It is seen in
patients who have undergone a cardiorespira-
tory arrest, regained consciousness afterwards,
and then developed myoclonus days or weeks
after the event. Accurate distinction between
myoclonic status epilepticus and Lance-Adams
syndrome is vital, as they have very different
prognoses. The different pathophysiologies and
distinguishing clinical features of these two
conditions are highlighted [21, 22].
12. Propofol infusion syndrome. This is a rare
condition characterized by the occurrence of
unexplained lactic acidosis, lipemia, rhabdomyo-
lysis, cardiovascular collapse, and acquired
Brugada-like electrocardiographic (ECG) chan-
ges following high-dose propofol infusion over
prolonged periods of time [23]. An acquired
Brugada-like ECG pattern, or Brugada syndro-
me phenocopy in severely head-injured pa-
tients, is a sign of cardiac electrical instability
that predicts imminent cardiac death [24, 25].
Additionally, Brugada-like ECG pattern could
be caused by secondary severe hyperkalemia.
In a 48 year-old man after short-term infusion
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of an average dose of propofol, Mali et al. [26]
suspected that the hyperkalemia was a sign of
propofol infusion syndrome. The patient was
undergoing a video-assisted esophagectomy,
for which one-lung ventilation, with air/oxygen,
isoflurane, and continuous epidural analgesia
was supplemented with propofol infusion. In
the intraoperative period, the patient develo-
ped severe hyperkalemia with mild acidosis but
no cardiovascular failure. There were no other
evident causes of hyperkalemia as documen-
ted by laboratory data. The procedure was
abandoned and the patient was taken to post-
operative recovery, where his potassium levels
returned to normal after ten hours. Dramatic
cardiac conduction disturbances, prolonged QT
interval, idioventricular rhythm, tachyarrhyth-
mias, and ventricular fibrillation are observed
in the setting of only mild metabolic acidosis
and a good ventricular function is possible [27].
At the basis of the syndrome lies an imbalance
between energy utilization and demand, resulting
in cell dysfunction and ultimately necrosis of cardi-
ac and peripheral muscle cells. In symptomatic pa-
tients with Brugada syndrome (syncope or sudden
death recovered) with positive pilsicainide challenge
test, routine monitors, right precordial lead of the
ECG, and an external defibrillator were installed by
Inamura et al. [28] prior to anesthesia. The authors
administered propofol/midazolam for induction, and
propofol/sevoflurane combined with fentanyl for
maintenance of anesthesia. Atropine and ephedrine
were administered to decrease vagal tone. No ECG
change or arrhythmia was observed perioperatively
in six patients studied. Several new case reports and
reviews, as well as a number of experiments, have
contributed significantly to our increased under-
standing of the cause of the syndrome. Uncertainty
remains as to whether a genetic susceptibility ex-
ists. Nonetheless, the growing number of case re-
ports has made it possible to identify several risk
factors. Propofol infusion syndrome is a rare but fre-
quently lethal complication of propofol use.
Possible etiologies of
propofol infusion syndrome
Table 2 summarizes the possible etiologies of
propofol infusion syndrome.
Long-term propofol abuse for recreational pur-
poses has been mentioned in literature. In a case
report, a strong positive reaction for tumor necro-
sis factor alpha in cardiac myocytes and a diffuse
apoptotic process in the heart specimens and mul-
tiple needle marks on the hands and forearms, as
well as a propofol concentration in the hair exam-
ined (0.73 mg/g), were observed [29].
Combined with fentanyl (an opioid), propofol is
used to alleviate pain [30]. It is used as sedation for
mechanically ventilated adults and procedural se-
dation. It is associated with significant mortality and
morbidity as a consequence of propofol infusion syn-
drome, especially at high infusion rates for pro-
longed periods [6].
Discussion and conclusions
The use of propofol for extended periods, and
in a high dose, may lead to the feared and rare pro-
pofol infusion syndrome. A significant mechanism
is the capacity of the drug in such conditions to
cause a non-traumatic form of rhabdomyolysis with
a release of the breakdown products of damaged
muscle cells into the bloodstream; some of these,
such as myoglobin, are harmful to the kidneys and
may lead to acute kidney failure. This acute renal
failure may result in retention of urea and creatinin
and non-nitrogenous waste products normally ex-
creted by the kidney. Depending on the severity and
duration of the renal dysfunction, this accumulation
is accompanied by metabolic acidosis and hyper-
kalemia (elevated potassium levels), changes in
body fluid balance, and effects on many other or-
gan systems. It can be characterized by oliguria or
anuria, although nonoliguric acute renal failure may
occur. It is a serious disease and is treated as a med-
ical emergency. The increase of serum potassium
could be responsible for the electrocardiographic
Brugada type 1 pattern.
As a consequence of infusion in high doses of
propofol from the point of view of ECG, the features
are ECG with upwardly convex elevation from V1
to V3 (Brugada-like ECG pattern). The development
Table 2. Possible etiologies of propofol infusion
syndrome.
Traumatic brain injury: these patients are particula-
ry at risk of developing this complication because
large doses of propofol are commonly used to con-
trol intracranial pressure (infusion rate of £ 4 mg/kg
per hour), whereas vasopressors are administered
to augment cerebral perfusion pressure
Induction and maintenance of general anesthesia
Sedation of mechanically ventilated adults and pro-
cedural sedation
Treatment of refractory status epilepticus with high
infusion rates for prolonged periods [6]
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of this acquired form of Brugada-like syndrome is
a sign of electric instability and a predictor of immi-
nent sudden death [31]. Severe hypercalcemia may
precipitate ECG Brugada-like pattern [32, 33].
Chronic renal insufficiency has been described
transitorily with hypercalcemia and reversed with
dialysis [34]. The ECG shown in Figure 1 is a case
of severe hypercalcemia with ECG Brugada-like
pattern.
Lactic acidosis observed in propofol infusion
syndrome is a condition characterized by lactate
levels > 5 mmol/L and serum pH < 7.35. The Co-
hen-Woods classification categorizes causes of lac-
tic acidosis into two types: A and B [35]:
— Type A: decreased perfusion or oxygenation;
— Type B:
• B1: Underlying diseases (sometimes cau-
sing type A),
• B2: Medication or intoxication,
• B3: Inborn error of metabolism.
Probably, lactic acidosis observed in propo-
fol infusion syndrome is a mixture of A (tissue hy-
poxia and hypoperfusion secondary to hyopten-
sion) and B2.
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